Therapeutic cancer targeting peptides, Peptide Science: Original Research on Biomolecules, vol.66, issue.3, pp.184-199, 2002. ,
,
DNA substrate dependence of p53-mediated regulation of double-strand break repair, Molecular and cellular biology, vol.22, issue.17, pp.6306-6317, 2002. ,
Ligand-targeted therapeutics in anticancer therapy, Nature Reviews Cancer, vol.2, issue.10, p.750, 2002. ,
Pathways governing G1/S transition and their response to DNA damage, FEBS letters, vol.490, issue.3, pp.117-122, 2001. ,
Suppression of human colorectal carcinoma cell growth by wild-type p53, Science, issue.4971, pp.912-915, 1990. ,
DNA damage checkpoints: from initiation to recovery or adaptation. Current opinion in cell biology, vol.19, pp.238-245, 2007. ,
DNA methylation and gene silencing in cancer, Nature Reviews Clinical Oncology, vol.2, issue.S1, p.4, 2005. ,
DNA hypermethylation in tumorigenesis: epigenetics joins genetics, Trends Genet, vol.16, p.168174, 2000. ,
Current strategies for the development of peptidebased anticancer therapeutics, vol.11, pp.713-726, 2005. ,
p53 isoforms can regulate p53 transcriptional activity, Genes & development, vol.19, issue.18, pp.2122-2137, 2005. ,
Structural details on mdm2-p53 interaction, Journal of Biological Chemistry, vol.280, issue.46, pp.38795-38802, 2005. ,
Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis, Science, issue.5660, pp.1010-1014, 2004. ,
Extensive post-translational modication of active and inactivated forms of endogenous p53, Mol Cell Proteomics, p.24056736, 2013. ,
Anti-Cancer Activity of Maize Bioactive Peptides, Frontiers in chemistry, vol.5, p.44, 2017. ,
,
Structure-based design of spiro-oxindoles as potent, specic small-molecule inhibitors of the MDM2¡ p53 interaction, Journal of medicinal chemistry, vol.49, issue.12, pp.3432-3435, 2006. ,
Protein identication and analysis tools on the ExPASy server, The proteomics protocols handbook, pp.571-607, 2005. ,
Dierential regulation of p53 target genes: it's (core promoter) elementary, Genes & development, vol.24, issue.2, pp.111-114, 2010. ,
Molecular characterization of the retinoblastoma susceptibility gene, Biochimica et Biophysica Acta (BBA)-Reviews on Cancer, vol.1155, issue.1, pp.43-61, 1993. ,
DNA methylation inhibitors in cancer: recent and future approaches, Biochimie, vol.94, issue.11, pp.2280-2296, 2012. ,
An oncogene-induced DNA damage model for cancer development, science, issue.5868, pp.1352-1355, 2008. ,
Inhibition of cyclin-dependent kinases by p21, Molecular biology of the cell, vol.6, issue.4, pp.387-400, 1995. ,
Induction of p21 by p53 following DNA damage inhibits both Cdk4 and Cdk2 activities, Oncogene, vol.24, issue.18, p.2929, 2005. ,
Targeting the ubiquitin system in cancer therapy, Nature, vol.458, issue.7237, p.438, 2009. ,
Targeting tumor suppressor p53 for cancer therapy: strategies, challenges and opportunities, 25. International Human Genome Sequencing Consortium, vol.15, issue.1, p.860, 2001. ,
,
Small molecule RITA binds to p53, blocks p53HDM2 interaction and activates p53 function in tumors, Nature medicine, vol.10, issue.12, p.1321, 2004. ,
Ribosomal stalling during translation: providing substrates for ribosome-associated protein quality control. Annual review of cell and developmental biology, vol.33, pp.343-368, 2017. ,
Cancer. Death and methylation, Nature, vol.409, issue.6817, pp.141-143, 2001. ,
URL : https://hal.archives-ouvertes.fr/hal-00868358
The isoforms of the p53 protein. Cold Spring Harbor perspectives in biology, vol.2, p.927, 2010. ,
Modes of p53 regulation, Cell, vol.137, issue.4, pp.609-622, 2009. ,
DNA methylation inhibitors in the treatment of leukemias, myelodysplastic syndromes and hemoglobinopathies: clinical results and possible mechanisms of action, Current topics in microbiology and immunology, vol.249, pp.135-164, 2000. ,
, , 2012.
, Design of Cyclic Peptides Featuring Proline Predominantly in the cis Conformation under Physiological Conditions, ChemBioChem, vol.13, issue.14, pp.2122-2127
Milestones in cell division: to cycle or not to cycle: a critical decision in cancer, Nature Reviews Cancer, vol.1, issue.3, p.222, 2001. ,
The gene for human p53 cellular tumor antigen is located on chromosome 17 short arm (17p13), Proceedings of the National Academy of Sciences, vol.83, pp.130-134, 1986. ,
,
Molecular insights into protein synthesis with proline residues, EMBO reports, p.201642943, 2016. ,
The p53Mdm2 module and the ubiquitin system, Seminars in cancer biology, vol.13, pp.49-58, 2003. ,
DNA methylation: the nuts and bolts of repression, Journal of cellular physiology, vol.213, issue.2, pp.384-390, 2007. ,
p53 mutations in cancer, Nature cell biology, vol.15, issue.1, 2013. ,
p53/p63/p73 isoforms: an orchestra of isoforms to harmonise cell dierentiation and response to stress, Cell death and dierentiation, vol.13, issue.6, p.962, 2006. ,
Targeting MDM2-p53 interaction for cancer therapy: are we there yet, Current medicinal chemistry, vol.21, issue.5, pp.553-574, 2014. ,
Decision making by p53: life, death and cancer. Cell death and dierentiation, vol.10, p.431, 2003. ,
Mutational spectra of human cancer, Human genetics, vol.125, issue.5-6, pp.493-506, 2009. ,
, , 2000.
, Single-site methylation within the p53 promoter region reduces gene expression in a reporter gene construct: possible in vivo relevance during tumorigenesis, Cancer research, vol.60, issue.3, pp.588-594
Future of monoclonal antibodies in the treatment of hematologic malignancies, Cancer Control, vol.9, pp.152-166, 2002. ,
Transcriptional Activation of the p53 Tumor Suppressor Gene Provides a Rapid Protective Mechanism against DNA Damage during S-phase of the Cell Cycle, J Leuk (Los Angel), vol.1, p.102, 2013. ,
,
Discovery of specic inhibitors of human USP7/HAUSP deubiquitinating enzyme, Chemistry & biology, vol.19, issue.4, pp.467-477, 2012. ,
,
Targeted disruption of the three Rb-related genes leads to loss of G1 control and immortalization, Genes & development, vol.14, issue.23, pp.3037-3050, 2000. ,
Involvement of p53 mutation and mismatch repair proteins dysregulation in NNK-induced malignant transformation of human bronchial epithelial cells, 2014. ,
CpG Methylation Inactivates the Transcriptional Activity of the Promoter of the Humanp53Tumor Suppressor Gene, Biochemical and biophysical research communications, vol.235, issue.2, pp.403-406, 1997. ,
Apaf-1 and caspase-9 in p53-dependent apoptosis and tumor inhibition, Science, vol.284, p.159, 1999. ,
Inactivation of the apoptosis eector Apaf-1 in malignant melanoma, Nature, vol.409, issue.6817, p.207, 2001. ,
Zebrash models of p53 functions. Cold Spring Harbor perspectives in biology, 1123. ,
Cancer treatment using peptides: current therapies and future prospects, Journal of amino acids, 2012. ,
Improving stability of peptide drugs through chemical modications, Oligos and Peptides, vol.32, pp.35-38, 2014. ,
Mutations in Cancer Cause Gain of Cysteine, Histidine, and Tryptophan at the Expense of a Net Loss of Arginine on the Proteome Level, Biomolecules, vol.7, issue.3, p.49, 2017. ,
MDM2 inhibitors for cancer therapy, Trends in molecular medicine, vol.13, issue.1, pp.23-31, 2007. ,
Cancer genes and the pathways they control, Nature medicine, vol.10, issue.8, p.789, 2004. ,
Surfing the p53 network, Nature, vol.408, issue.6810, p.307, 2000. ,
p53 in health and disease, Nature reviews Molecular cell biology, vol.8, issue.4, p.275, 2007. ,
Peptide-based treatment: a promising cancer therapy, Journal of immunology research, 2015. ,
Targeting the MDM2-p53 protein-protein interaction for new cancer therapeutics, Proteinprotein interactions, pp.57-79, 2012. ,
Peptides in cancer nanomedicine: drug carriers, targeting ligands and protease substrates, Journal of controlled release, vol.159, issue.1, pp.2-13, 2012. ,
Antioxidant peptides from corn gluten meal: orthogonal design evaluation, Food Chem, vol.187, 2015. ,
Arginine-glycine-aspartic acid (RGD)-peptide binds to both tumor and tumor-endothelial cells in vivo, Cancer research, vol.62, issue.18, pp.5139-5143, 2002. ,